A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer

Clinical trial NCT05802342 · UNKNOWN

Trial details

NCT number: NCT05802342
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients

Start date: 2023-04-20
Primary completion: 2024-12-31
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.